Option Care Health, Inc. research snapshot
OPCH AI stock analysis currently reads Option Care Health as the largest independent U.S. home and alternate-site infusion services provider, with steady revenue near $5.7 billion, modest net margins around 3.6%, and a business positioned for the long-term site-of-care shift from hospital to home. At the July 12, 2026 research cutoff, the July 10 close was $21.57, market capitalization was about $3.39 billion on roughly 157 million shares, and the stock has declined about 32% year to date from its $31.86 open. The core debate is whether the pullback creates a value opportunity in a defensive healthcare services business or whether margin pressure, reimbursement risk, elevated short interest near 8.6%, and modest growth justify the lower valuation. This page uses scenario analysis, not a certain price prediction, and it is informational research rather than investment advice.
Current price
$21.57
Market cap
$3.39 billion
AI score
63 / 100
Rating
Leading home infusion provider with steady revenue, low margins, high short interest, and site-of-care tailwinds
Trend status
Near the bottom of the 52-week range with a sharp YTD decline of about 32%
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Option Care Health is the largest independent provider of home and alternate-site infusion services in the U.S., administering injectable therapies through a nationwide pharmacy and nursing network serving all 50 states and Puerto Rico. | High |
| Moat | The moat comes from scale, geographic footprint, payer relationships, pharmacy infrastructure, nursing network, and regulatory compliance. It is a moderate moat because large hospital systems and national pharmacy chains could compete more aggressively. | Medium |
| Management | CEO Michael Adkins has focused on clinical capabilities, digital platforms, patient support services, and partnership development. Insiders have net bought $1.5 million in stock over the last three months with zero insider selling, a positive alignment signal. | Medium-high |
| Financial trend | FY2025 revenue was about $5.66 billion with net income near $207 million and 3.64% net margins. Q1 2026 EPS of $0.40 beat consensus estimates of $0.37. Revenue growth has been steady but single-digit, and margins remain thin. | High |
| Valuation | At $21.57, OPCH trades at 16.72x trailing EPS, 13.15x forward EPS, 0.62x price to sales, 2.58x book value, and 20.16x levered free cash flow. A verified three-scenario model produced a base case near $39.30, with downside if growth stalls or margins compress. | Medium-high for math, medium for forward assumptions |
| Technical trend | OPCH is near the bottom of its 52-week range of $18.01 to $36.80, down about 32% YTD. The stock trades below its major moving averages after a sustained decline, with momentum still negative but showing signs of stabilization in the $19 to $22 zone. | Medium |
| Risk level | Risk is elevated for a mid-cap healthcare services company. Key risks include reimbursement policy changes by CMS and commercial payers, margin pressure from drug costs and labor, competition from hospital systems and national pharmacies, and elevated short interest of 8.58% of float. | Medium-high |
| AI confidence | High confidence for company filings, market-cap verification, revenue, net income, cash, debt, insider trading, and institutional holdings. Lower confidence for reimbursement policy trajectory, competitive dynamics, volume growth, and margin expansion timing. | High data confidence |
| Investment certainty | Medium-Low certainty. The business model has defensive healthcare characteristics and a secular site-of-care shift tailwind, but the investment case depends on whether management can expand thin margins, navigate reimbursement risk, and reduce the high short interest over time. | Medium-Low |
OPCH AI stock forecast
The OPCH AI stock forecast uses three scenarios based on EPS growth and valuation multiples rather than a single deterministic price prediction. The base case assumes the company continues steady single-digit revenue growth with gradual margin improvement. The bullish case depends on faster volume growth, better reimbursement, and margin expansion. The bearish case reflects margin compression, reimbursement cuts, or operational setbacks.
$45 to $55
More likely if OPCH accelerates organic growth above 10%, expands operating margins through scale and cost efficiency, maintains favorable reimbursement trends, and the market applies a 22x forward PE multiple. The verified three-scenario model produced about $54.90 using 15% EPS growth and a 22x terminal multiple.
$30 to $40
More likely if OPCH tracks 8% to 10% EPS growth, holds steady revenue trends driven by the site-of-care shift, maintains current margins, and trades near 18x forward earnings. The verified model base case was about $39.30.
$18 to $24
More likely if reimbursement pressure increases, margins stay compressed or shrink, volume growth decelerates, or the market assigns a lower 12x PE multiple reflecting lower growth expectations. The verified bear model produced about $21.50, near the current stock price.
OPCH AI technical analysis
OPCH AI technical analysis starts from the $21.57 close on July 10, 2026. The stock is near the bottom of its 52-week range after a sustained decline from the $36.80 high. The $18 to $20 zone is the critical support area, while resistance emerges near $25 and then $30. Technical levels should be checked against Q2 2026 earnings on or around July 29, 2026, reimbursement updates, volume trends, and short interest changes.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $21.57 | Latest verified close used for this page, reported for July 10, 2026. |
| Support zone | $18 to $20 | This zone covers the 52-week low of $18.01 and the recent consolidation area. A break below it would signal further downside risk. |
| Near resistance | $22 to $25 | The stock needs to reclaim the $22 area first, then the $25 level, to establish a short-term uptrend. |
| Key resistance | $30 to $32 | This area aligns with the YTD opening price of $31.86 and represents a major recovery threshold. |
| 52-week high | $36.80 | The 52-week high serves as the upper reference for the full recovery case. |
| Momentum | RSI estimated near 35-40 | RSI in the low-to-mid 30s would suggest the stock is approaching oversold territory, which could attract均值回归资金. |
| Volume | Average volume about 2.4 to 3.3 million shares | Recent volume has been below the average, suggesting the selloff may be exhausting. A volume spike on an up day would be a positive reversal signal. |
| Volatility | Beta 0.65 | OPCH has a lower beta than the broad market, but the 32% YTD decline shows it can still have significant drawdowns during company-specific stress. |
| Invalidation | Break below $18 or guidance cut | A close below the $18.01 52-week low, a downward revision to EPS guidance, or an unfavorable reimbursement policy change would weaken the base case. |
OPCH AI trading strategy
The OPCH AI trading strategy is a rules-based framework, not personalized advice. It should be monitored through live price, Q2 2026 earnings on or around July 29, 2026, volume trends, short interest changes, reimbursement policy updates, and company guidance.
Wait for OPCH to establish a base above the $22 area with increasing volume and positive RSI divergence. Confirmation improves if Q2 2026 results show EPS growth, margin stability, and maintained or raised guidance.
Reduce confidence if the stock breaks below the $18 52-week low, if volume expands on further down days, or if reimbursement or competitive news turns negative.
Use pullbacks toward the $18 to $20 support zone as a watchlist condition only if the company reports stable operating trends, insider buying continues, and short interest does not spike further.
Do not treat the 52-week low as an automatic floor. A break below $18 with volume would suggest a new leg down. Position sizing should account for the elevated short interest and thin margins.
Track quarterly revenue growth, EPS, gross and operating margins, free cash flow, net debt to EBITDA, same-store or organic volume growth, reimbursement updates, and insider buying or selling patterns.
A combination of shrinking margins, negative guidance revisions, rising short interest, insider selling, and a close below $18 would override any bullish chart setup.
Investment research summary
Option Care Health is paid to administer complex injectable therapies to patients in their homes rather than in hospitals. Payers and providers benefit from lower costs, and patients benefit from convenience and comfort, driving a secular shift toward alternate-site infusion.
The moat comes from national scale, a specialized infusion pharmacy and nursing network, payer contracts, regulatory know-how, and relationships with pharmaceutical manufacturers. The moat is not impenetrable because hospital systems and large pharmacy chains like CVS and Walgreens could invest to compete in home infusion.
The thesis can fail if the Centers for Medicare and Medicaid Services (CMS) or commercial payers cut reimbursement rates for infused drugs, if drug cost inflation compresses margins, if labor shortages increase nursing costs, if competition from hospital systems or pharmacies intensifies, or if the company takes on too much debt.
CEO Michael Adkins has emphasized clinical capability investment, digital patient support platforms, and payer and manufacturer partnerships. The insider buying signal of $1.5 million in net purchases over the last three months with zero sales is a constructive alignment indicator.
The long-term trend is favorable: the shift of infusion therapy from hospital to home settings is a multi-decade secular trend driven by cost containment, patient preference, and technology enabling remote care. This creates a durable tailwind for the home infusion industry.
The verified scenario model produced about $54.90 in the bull case, $39.30 in the base case, and $21.50 in the bear case using forward EPS estimates. At $21.57, the stock prices in a bearish outcome. The margin of safety depends on whether the company can grow EPS at 8% to 10% annually versus the 3% embedded in the bear case.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| OPCH price | $21.57 close on July 10, 2026 | MarketBeat stock overview page | July 12, 2026 |
| Market capitalization | $3.39 billion, verified as $21.57 x 157.03 million shares | financial_rigor.py market cap verification | July 12, 2026 |
| Shares outstanding | 157.03 million shares outstanding | MarketBeat stock overview page | July 12, 2026 |
| Revenue TTM | $5.66 billion (consensus), cross-validated against Yahoo Finance at $5.67B and MarketBeat at $5.65B with 0.18% deviation | Yahoo Finance and MarketBeat | July 12, 2026 |
| Net income TTM | $206.89 million (consensus), cross-validated against Yahoo Finance at $206.19M and MarketBeat at $207.59M with 0.34% deviation | Yahoo Finance and MarketBeat | July 12, 2026 |
| Q1 2026 earnings | $0.40 EPS, beating consensus estimate of $0.37 by $0.03. Revenue up 1.3% year over year. | MarketBeat earnings data | July 12, 2026 |
| Valuation and financial metrics | 16.72x trailing PE, 13.15x forward PE, 1.20 PEG, 0.62 price to sales, 2.58 price to book, 20.16x P/FCF, 4.96% FCF yield, 0.85 debt to equity, EV $4.53B | MarketBeat and Yahoo Finance | July 12, 2026 |
| Balance sheet and cash | $181.85M total cash, 94.01% total debt to equity, $168.69M levered free cash flow TTM | Yahoo Finance statistics page | July 12, 2026 |
| Analyst consensus and targets | Moderate Buy consensus from 14 analysts. Average price target $30.54, high $39.00, low $22.00. Goldman Sachs initiated with Neutral and $22 target on June 8, 2026. | MarketBeat analyst forecasts | July 12, 2026 |
| Insider and institutional activity | 1.70% insider ownership with $1.55M net insider buying over 3 months (zero sales). 98.05% institutional ownership. Short interest at 8.58% of float with 4.67 days to cover. | MarketBeat insider and short interest data | July 12, 2026 |
| Technical indicators | 52-week range $18.01 to $36.80. Beta 0.65. Average volume 2.4M to 3.3M shares. YTD decline of approximately 32.3% from $31.86 open. | MarketBeat and Yahoo Finance | July 12, 2026 |
This OPCH AI stock analysis page is an informational tool only and is not investment advice, tax advice, or a recommendation to buy or sell any security. Forecast ranges are scenarios based on available public data as of July 12, 2026 and may be wrong if financial results, reimbursement policies, competitive dynamics, margins, management execution, or market conditions change. Home infusion services are subject to regulatory and reimbursement risk. Investing in mid-cap healthcare stocks carries risks including but not limited to margin pressure, regulatory changes, and market volatility.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
